Objectives: Novel iniparib is not a typical PARP inhibitor; its exact mechanism is still being elucidated but it has shown anticancer activity. The primary outcome measure is overall survival.
Key entry or exclusion criteria: Stage IV squamous cell lung cancer must be newly diagnosed; at least 12 months must have passed if patient had adjuvant therapy for early-stage lung cancer.
Locations: 148 sites.
Goal: 780 patients.
Study sponsor: Sanofi-Aventis in collaboration with BiPar Sciences
Link for more information: http://clinicaltrials.gov/ct2/show/NCT01082549
NIH clinical trial identifier: NCT01082549